Literature DB >> 17540785

Exacerbations of chronic obstructive pulmonary disease.

B R Celli1, P J Barnes.   

Abstract

Exacerbations of chronic obstructive pulmonary disease are of major importance in terms of their prolonged detrimental effects on patients, the acceleration in disease progression and high healthcare costs. There is still debate about how exacerbations should be defined and graded, and their mechanisms are poorly understood. The major causal agents are either bacteria or viral infections, or a combination of the two. Noninfective causes include air pollution and pulmonary embolus but, in some patients, no cause is identified. Exacerbations represent an increase in the inflammation that is present in the stable state, with increased numbers of inflammatory cells (particularly neutrophils), cytokines, chemokines and proteases in the airways, and increased concentrations of certain cytokines and C-reactive protein in the blood. There are presently no reliable biomarkers with which to predict exacerbations. Exacerbations have a long-lasting adverse influence on health status. High doses of bronchodilators are the mainstay of treatment and systemic corticosteroids have some benefit. The routine use of antibiotics remains controversial but they are of benefit with exacerbations of a bacterial origin. Noninvasive ventilation is beneficial in preventing the need for intubation and its important complications but it is not certain whether its use in stable patients prevents exacerbations. Although important advances have been made, more effective treatments are needed in the future for prevention and treatment of exacerbations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540785     DOI: 10.1183/09031936.00109906

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  110 in total

Review 1.  Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Authors:  Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 2.  Clinical review: Endobronchial valve treatment for emphysema.

Authors:  Nabil Jarad
Journal:  Chron Respir Dis       Date:  2016-02-15       Impact factor: 2.444

Review 3.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

4.  Inappropriate Utilization of Antibiotics in COPD Exacerbations.

Authors:  Yelda Varol; Zuhal Karakurt; Ali Kadri Çırak; Hülya Doğan Şahin; Cenk Kıraklı; Berna Kömürcüoğlu
Journal:  Turk Thorac J       Date:  2020-11-01

5.  Midkine is expressed and differentially processed during chronic obstructive pulmonary disease exacerbations and ventilator-associated pneumonia associated with Staphylococcus aureus infection.

Authors:  Helena M Linge; Cecilia Andersson; Sara L Nordin; Anders I Olin; Ann-Cathrine Petersson; Matthias Mörgelin; Amanda Welin; Johan Bylund; Leif Bjermer; Jonas Erjefält; Arne Egesten
Journal:  Mol Med       Date:  2013-09-30       Impact factor: 6.354

6.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

7.  A novel function of MUC18: amplification of lung inflammation during bacterial infection.

Authors:  Qun Wu; Stephanie R Case; Maisha N Minor; Di Jiang; Richard J Martin; Russell P Bowler; Jieru Wang; John Hartney; Anis Karimpour-Fard; Hong Wei Chu
Journal:  Am J Pathol       Date:  2012-12-17       Impact factor: 4.307

Review 8.  Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease.

Authors:  Neil MacIntyre; Yuh Chin Huang
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

9.  "Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.

Authors:  Konstantinos Kostikas; Demosthenes Bouros
Journal:  BMC Pulm Med       Date:  2010-09-15       Impact factor: 3.317

Review 10.  The empirical foundations of telemedicine interventions for chronic disease management.

Authors:  Rashid L Bashshur; Gary W Shannon; Brian R Smith; Dale C Alverson; Nina Antoniotti; William G Barsan; Noura Bashshur; Edward M Brown; Molly J Coye; Charles R Doarn; Stewart Ferguson; Jim Grigsby; Elizabeth A Krupinski; Joseph C Kvedar; Jonathan Linkous; Ronald C Merrell; Thomas Nesbitt; Ronald Poropatich; Karen S Rheuban; Jay H Sanders; Andrew R Watson; Ronald S Weinstein; Peter Yellowlees
Journal:  Telemed J E Health       Date:  2014-06-26       Impact factor: 3.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.